Most "best longevity drugs" lists rank by popularity. This one ranks by what's actually been measured in trials — and several popular compounds rank lower than you'd expect.
Ranking is by Geroevidence's four-tier evidence ladder — Strong, Moderate, Emerging, Insufficient — based on trial volume and outcome type, not on what's trending. This list does not constitute a recommendation to use any of these compounds; it's a structured summary of where the published evidence currently stands.
Taurine, berberine, spermidine, Urolithin A, and fisetin currently lack the minimum published human trial or strong ITP-style data Geroevidence requires for a formal tier. That doesn't mean "no evidence" — several have promising mouse or Phase II signals — it means the human evidence base hasn't yet crossed the threshold. See each compound's full profile for current status.
The compounds with the most online attention — NMN, senolytics, taurine — are not the ones with the strongest published evidence. The two interventions with genuine Phase III outcome data, GLP-1 agonists and SGLT2 inhibitors, are approved drugs for diabetes and weight management first, longevity-adjacent second. That asymmetry between hype and evidence is exactly what this ranking is built to surface.